Kimberly J. Popovits

Filings by Kimberly J. Popovits span 6 companies, the busiest being Genomic Health Inc, 10x Genomics, Inc. and Kiniksa Pharmaceuticals International, plc. We count 156 filings; the first trade dates from 12 January 2016 and the latest from 4 June 2026.

The open-market side counts 1 purchase for €70k alongside 75 sales for €28.8M. On balance, insiders were net sellers of €28.7M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 16 share grants and 42 option exercises.

Most recently, on 8 June 2026, the filings show a share grant in 10x Genomics, Inc. The latest purchase dates back some time: it was published 2,072 days ago, on 19 February 2021. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.